These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23658433)

  • 1. Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?
    Tamma PD; Powers JH
    Clin Infect Dis; 2013 Aug; 57(4):624-5. PubMed ID: 23658433
    [No Abstract]   [Full Text] [Related]  

  • 2. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
    Dudley MN; Ambrose PG; Bhavnani SM; Craig WA; Ferraro MJ; Jones RN;
    Clin Infect Dis; 2013 May; 56(9):1301-9. PubMed ID: 23334813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Clinical and Laboratory Standards Institute 2008 and 2010 guidelines in interpreting susceptibility of enterobacteriaceae isolates.
    Agrawal GN; Shevade SU
    Indian J Pathol Microbiol; 2014; 57(3):518-9. PubMed ID: 25118774
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae.
    Bunnell KL; Wenzler E; Harrington AT; Danziger LH
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):335-336. PubMed ID: 29395714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High resistance to fourth-generation cephalosporins among clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases isolated in Portugal.
    Fernandes R; Gestoso A; Freitas JM; Santos P; Prudêncio C
    Int J Antimicrob Agents; 2009 Feb; 33(2):184-5. PubMed ID: 18926667
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.
    Bartsch SM; Huang SS; Wong KF; Slayton RB; McKinnell JA; Sahm DF; Kazmierczak K; Mueller LE; Jernigan JA; Lee BY
    J Clin Microbiol; 2016 Nov; 54(11):2757-2762. PubMed ID: 27582516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints.
    Turnidge JD;
    Clin Infect Dis; 2011 Apr; 52(7):917-24. PubMed ID: 21427400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering of third generation cephalosporin breakpoints.
    Thomson KS
    Clin Infect Dis; 2013 Dec; 57(11):1663-4. PubMed ID: 24006448
    [No Abstract]   [Full Text] [Related]  

  • 12. Susceptibility to penicillin derivatives among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Diagn Microbiol Infect Dis; 2017 Jan; 87(1):71-73. PubMed ID: 27769572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rates of antimicrobial co-resistance among Enterobacteriaceae: comparative analysis between clinical isolates resistant and susceptible to third-generation cephalosporins.
    Goyanes MJ; Cercenado E; Insa R; Morente A; Alcalá L; Bouza E
    Rev Esp Quimioter; 2007 Jun; 20(2):216-21. PubMed ID: 17893759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of acquired resistance to third-generation cephalosporins in Enterobacteriaceae in a Tunisian hospital 1993-2001.
    Boutiba-Ben Boubaker I; Ghozzi R; Ben Abdallah H; Mamlouk K; Kamoun A; Ben Redjeb S
    Clin Microbiol Infect; 2004 Jul; 10(7):665-7. PubMed ID: 15214883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus statement on the adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in clinical microbiology laboratories in Taiwan.
    Hsueh PR; Ko WC; Wu JJ; Lu JJ; Wang FD; Wu HY; Wu TL; Teng LJ
    J Microbiol Immunol Infect; 2010 Oct; 43(5):452-5. PubMed ID: 21075714
    [No Abstract]   [Full Text] [Related]  

  • 16. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
    Pottumarthy S; Deshpande LM; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):95-9. PubMed ID: 15964496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cephalothin is not a reliable surrogate marker for oral cephalosporins in susceptibility testing of Enterobacteriaceae causing urinary tract infection.
    López IA; Montes JC; Álvarez MJ; Mazarrasa CF; Martínez-Martínez L
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):412-416. PubMed ID: 27640080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.
    Chen YH; Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL
    J Infect; 2011 Apr; 62(4):280-91. PubMed ID: 21382411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England.
    Potz NA; Hope R; Warner M; Johnson AP; Livermore DM;
    J Antimicrob Chemother; 2006 Aug; 58(2):320-6. PubMed ID: 16735428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.